498 related articles for article (PubMed ID: 19297218)
1. MMP and TIMP alterations in asymptomatic and symptomatic severe recurrent carotid artery stenosis.
Sapienza P; Borrelli V; di Marzo L; Cavallaro A
Eur J Vasc Endovasc Surg; 2009 May; 37(5):525-30. PubMed ID: 19297218
[TBL] [Abstract][Full Text] [Related]
2. Metalloproteinases and their inhibitors are markers of plaque instability.
Sapienza P; di Marzo L; Borrelli V; Sterpetti AV; Mingoli A; Cresti S; Cavallaro A
Surgery; 2005 Mar; 137(3):355-63. PubMed ID: 15746792
[TBL] [Abstract][Full Text] [Related]
3. Metalloproteinase expression in carotid plaque and its correlation with plasma levels before and after carotid endarterectomy.
Taurino M; Raffa S; Mastroddi M; Visco V; Rizzo L; Torrisi MR; Faraglia V
Vasc Endovascular Surg; 2007 Dec-2008 Jan; 41(6):516-21. PubMed ID: 18166633
[TBL] [Abstract][Full Text] [Related]
4. Plasma MMP-9 - a marker of carotid plaque instability.
Loftus IM; Naylor AR; Bell PR; Thompson MM
Eur J Vasc Endovasc Surg; 2001 Jan; 21(1):17-21. PubMed ID: 11170872
[TBL] [Abstract][Full Text] [Related]
5. Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis.
Alvarez B; Ruiz C; Chacón P; Alvarez-Sabin J; Matas M
J Vasc Surg; 2004 Sep; 40(3):469-75. PubMed ID: 15337875
[TBL] [Abstract][Full Text] [Related]
6. Homocysteine and early re-stenosis after carotid eversion endarterectomy.
Assadian A; Rotter R; Assadian O; Senekowitsch C; Hagmüller GW; Hübl W
Eur J Vasc Endovasc Surg; 2007 Feb; 33(2):144-8. PubMed ID: 17067826
[TBL] [Abstract][Full Text] [Related]
7. Eversion carotid endarterectomy: a technical alternative that may obviate patch closure in women.
Darling RC; Mehta M; Roddy SP; Paty PS; Kreienberg PB; Ozsvath KJ; Chang BB; Shah DM
Cardiovasc Surg; 2003 Oct; 11(5):347-52. PubMed ID: 12958544
[TBL] [Abstract][Full Text] [Related]
8. Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease.
Jguirim-Souissi I; Jelassi A; Addad F; Hassine M; Najah M; Ben Hamda K; Maatouk F; Ben Farhat M; Bouslema A; Rouis M; Slimane MN
Am J Cardiol; 2007 Jul; 100(1):23-7. PubMed ID: 17599435
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
[TBL] [Abstract][Full Text] [Related]
10. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma.
Pennanen H; Kuittinen O; Turpeenniemi-Hujanen T
Eur J Haematol; 2008 Jan; 80(1):46-54. PubMed ID: 18028436
[TBL] [Abstract][Full Text] [Related]
11. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
[TBL] [Abstract][Full Text] [Related]
12. Markers of inflammation in patients with symptomatic and asymptomatic carotid artery stenosis: a case-control study.
Debing E; Peeters E; Demanet C; De Waele M; Van den Brande P
Vasc Endovascular Surg; 2008; 42(2):122-7. PubMed ID: 18421029
[TBL] [Abstract][Full Text] [Related]
13. Basic fibroblast growth factor mediates carotid plaque instability through metalloproteinase-2 and -9 expression.
Sapienza P; di Marzo L; Borrelli V; Sterpetti AV; Mingoli A; Piagnerelli R; Cavallaro A
Eur J Vasc Endovasc Surg; 2004 Jul; 28(1):89-97. PubMed ID: 15177237
[TBL] [Abstract][Full Text] [Related]
14. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
Hoffmann U; Bertsch T; Dvortsak E; Liebetrau C; Lang S; Liebe V; Huhle G; Borggrefe M; Brueckmann M
Scand J Infect Dis; 2006; 38(10):867-72. PubMed ID: 17008230
[TBL] [Abstract][Full Text] [Related]
15. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.
Wilson EM; Gunasinghe HR; Coker ML; Sprunger P; Lee-Jackson D; Bozkurt B; Deswal A; Mann DL; Spinale FG
J Card Fail; 2002 Dec; 8(6):390-8. PubMed ID: 12528092
[TBL] [Abstract][Full Text] [Related]
16. Role of platelet-derived growth factor and transforming growth factor beta1 the in the regulation of metalloproteinase expressions.
Borrelli V; di Marzo L; Sapienza P; Colasanti M; Moroni E; Cavallaro A
Surgery; 2006 Sep; 140(3):454-63. PubMed ID: 16934609
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinases (MMP-8, MMP-9) and the tissue inhibitors of metalloproteinases (TIMP-1, TIMP-2) in patients with fungal keratitis.
Rohini G; Murugeswari P; Prajna NV; Lalitha P; Muthukkaruppan V
Cornea; 2007 Feb; 26(2):207-11. PubMed ID: 17251814
[TBL] [Abstract][Full Text] [Related]
18. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip.
Masuhara K; Nakai T; Yamaguchi K; Yamasaki S; Sasaguri Y
Arthritis Rheum; 2002 Oct; 46(10):2625-31. PubMed ID: 12384920
[TBL] [Abstract][Full Text] [Related]
19. Multiple biological predictors for vulnerable carotid lesions.
Pelisek J; Rudelius M; Zepper P; Poppert H; Reeps C; Schuster T; Eckstein HH
Cerebrovasc Dis; 2009; 28(6):601-10. PubMed ID: 19844101
[TBL] [Abstract][Full Text] [Related]
20. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis.
Mühl D; Nagy B; Woth G; Falusi B; Bogár L; Weber G; Lantos J
J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
